* Trevena Inc reported a quarterly adjusted loss of 23 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -69 cents. The mean expectation of two analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -44 cents to -37 cents per share.
* Revenue fell 89.2% to $325.00 thousand from a year ago; analysts expected zero.
* Trevena Inc's reported EPS for the quarter was a loss of 23 cents.
* The company reported a quarterly loss of $4.89 million.
* Trevena Inc shares had fallen by 8.4% this quarter and lost 72.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 3.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Trevena Inc is $4.00 This summary was machine generated from LSEG data August 12 at 03:09 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.40 -0.23 Beat
Mar. 31 2024 -0.47 -0.36 Beat
Dec. 31 2023 -0.38 -1.06 Missed
Sep. 30 2023 -0.15 -0.57 Missed
Comments